Fig. 3.
Kaplan-Meier curves of OS for individual patient data extracted from combination systemic therapies for aHCC. Anti-PD-(L)1/VEGF Ab, anti-programmed death-1/programmed death-ligand-1 pathway plus vascular endothelial growth receptor monoclonal antibody; Ate-Cab, atezolizumab-cabozantinib; T300+D, tremelimumab-durvalumab.